For research use only. Not for therapeutic Use.
Lixivaptan, laso known as CRTX-080; VPA-985; WAY-VPA-985, is a potent, orally active, non-peptide, selective vasopressin 2 receptor antagonist. Lixivaptan works by reducing the action of the hormone vasopressin that blocks fluid excretion. Lixivaptan acts by blocking vasopressin, an anti-diuretic hormone that causes the kidneys to retain water. When the body needs to remain hydrated under certain conditions, vasopressin can have protective effects.
| Catalog Number | R050672 |
| CAS Number | 168079-32-1 |
| Synonyms | N-[3-Chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl-benzamide; VPA 985; WAY-VPA 985; |
| Molecular Formula | C27H21ClFN3O2 |
| Purity | ≥95% |
| Target | Vasopressin Receptor |
| Storage | -20°C |
| InChIKey | PPHTXRNHTVLQED-UHFFFAOYSA-N |
| Reference | </br>1:Development and validation of HPLC-MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. Khady AA, Alrabiah H, Attwa MW, Attia S, Mostafa GAE.Biomed Chromatogr. 2017 May 10. doi: 10.1002/bmc.4007. [Epub ahead of print] PMID: 28493402 </br>2:Treatment of hyponatremia: the role of lixivaptan. Liamis G, Filippatos TD, Elisaf MS.Expert Rev Clin Pharmacol. 2014 Jul;7(4):431-41. doi: 10.1586/17512433.2014.911085. Epub 2014 Apr 28. Review. PMID: 24766294 </br>3:Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia. Bowman BT, Rosner MH.Core Evid. 2013;8:47-56. doi: 10.2147/CE.S36744. Epub 2013 Jul 11. PMID: 23874242 Free PMC Article</br>4:Lixivaptan and hyponatremia. Ring T.Kidney Int. 2013 Jun;83(6):1205-6. doi: 10.1038/ki.2013.39. No abstract available. PMID: 23728012 </br>5:Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment. Zmily HD, Alani A, Ghali JK.Expert Opin Drug Metab Toxicol. 2013 May;9(5):645-55. doi: 10.1517/17425255.2013.783566. Epub 2013 Apr 9. Review. PMID: 23570283 </br>6:Lixivaptan for hyponatremia–the numbers game. Borne RT, Krantz MJ.JAMA. 2012 Dec 12;308(22):2345-6. doi: 10.1001/jama.2012.54515. No abstract available. PMID: 23232892 </br>7:Lixivaptan: a vasopressin receptor antagonist for the treatment of hyponatremia. Rosner MH.Kidney Int. 2012 Dec;82(11):1154-6. doi: 10.1038/ki.2012.317. PMID: 23151986 Free Article</br>8:Hyponatraemia: Lixivaptan for euvolaemic hyponatraemia. Allison SJ.Nat Rev Nephrol. 2012 Nov;8(11):612. doi: 10.1038/nrneph.2012.204. Epub 2012 Sep 11. No abstract available. PMID: 22965690 </br>9:Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Abraham WT, Decaux G, Josiassen RC, Yagil Y, Kopyt N, Thacker HP, Mannelli M, Bichet DG, Orlandi C; HARMONY Study Group..Kidney Int. 2012 Dec;82(11):1215-22. doi: 10.1038/ki.2012.274. Epub 2012 Aug 29. PMID: 22932122 Free Article</br>10:Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Abraham WT, Hensen J, Gross PA, Bichet DG, Josiassen RC, Chafekar DS, Orlandi C; LIBRA Study Group..Kidney Int. 2012 Dec;82(11):1223-30. doi: 10.1038/ki.2012.275. Epub 2012 Aug 29. PMID: 22932119 Free Article |
